Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial

PUBT · 2d ago
Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial
  • Kura Oncology disclosed updated Phase 1a results already presented at KCRS 2026 for darlifarnib with cabozantinib in advanced clear cell renal cell carcinoma.
  • The combination produced durable tumor shrinkage in a pretreated, cabozantinib-naïve population, supporting continued development in later-line settings.
  • Safety looked manageable, broadly matching known profiles of the two drugs, with side effects handled mainly through dosing adjustments.
  • A randomized Phase 1b study is enrolling in the U.S. and EU, testing the combination versus cabozantinib alone to set a recommended Phase 3 dose.
  • Kura targets a registrational study in 2028, positioning the regimen as a potential option following immunotherapy-based treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270632PRIMZONEFULLFEED9778158) on July 27, 2026, and is solely responsible for the information contained therein.